Santiago Fontes, Medical Oncologist, Immuno-Oncology Specialist, shared a post on LinkedIn:
“BOT-BAL in MSS mCRC; Extended follow up
Promising advances in the treatment of microsatellite-stable metastatic colorectal cancer (MSS mCRC) at this year’s meeting.
A Phase 1 study evaluating the combination of botensilimab + balstilimab in patients without active liver metastases demonstrated encouraging long-term outcomes, including:
- 21% overall response rate
- Median overall survival of 21.2 months
- Durable responses lasting beyond two years in several patients
- A manageable safety profile with no new safety signals during extended follow-up
These findings highlight the potential of dual immune checkpoint inhibition to improve outcomes in a patient population that has traditionally had limited response to immunotherapy and few effective therapies.
It will be exciting to see how these results are further validated in ongoing Phase 3 studies.”
